Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002924 · ClinicalTrials.gov registry record
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
A clinical trial, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- 184
- Enrollment target
NCT00002924 is a clinical trial that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 184 participants.
The verdict
NCT00002924 has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- 184 participants
- Enrollment target
Study Summary
RATIONALE: Gene mutations may make prostate cancer cells unable to attach to androgens. This may permit the growth of prostate cancer. Gene testing may improve the identification of patients with advanced prostate cancer. PURPOSE: Clinical trial to study the androgen receptor gene in patients with prostate cancer that is not responsive to hormone therapy.
Interventions
- OTHER mutation analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 1997-01 |
| Est. Completion | 2006-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002924
The ClinicalTrials.gov registry entry for NCT00002924 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mutation analysis is the first listed.
NCT00002924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002924 about?
NCT00002924 is a clinical study titled "Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy". RATIONALE: Gene mutations may make prostate cancer cells unable to attach to androgens. This may permit the growth of prostate cancer. Gene testing may improve the identification of patients with advanced prostate cancer. PURPOSE: Clinical trial to study the androgen receptor gene in patients with ...
What is the current status of trial NCT00002924?
This trial is currently completed. The enrollment target is 184 participants. The study started on 1997-01. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00002924?
The interventions under investigation include: mutation analysis (OTHER).
Who is sponsoring clinical trial NCT00002924?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.